Argus Upgrades Zimmer Biomet (ZBH) to Buy

Argus upgraded Zimmer Biomet (NYSE: ZBH) from Hold to Buy with a price target of $140.00.

The firm said recent upbeat guidance suggests the company has overcome integration issues related to the Biomet merger and stabilized the combined sales force.

The firm is raising their adjusted EPS estimates to $7.92 from $7.75 for 2016 and to $8.70 from $8.50 for 2017

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $120.76 yesterday.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
• Freedom Broker Starts AngloGold Ashanti (AU) at Buy